GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Awakn Life Sciences Corp (OTCPK:AWKNF) » Definitions » Altman Z-Score

Awakn Life Sciences (Awakn Life Sciences) Altman Z-Score : -62.52 (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Awakn Life Sciences Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -62.02 is in distress zone. This implies bankruptcy possibility in the next two years.

Awakn Life Sciences has a Altman Z-Score of -62.52, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Awakn Life Sciences's Altman Z-Score or its related term are showing as below:

AWKNF' s Altman Z-Score Range Over the Past 10 Years
Min: -75.22   Med: -10.46   Max: 5.32
Current: -62.02

During the past 3 years, Awakn Life Sciences's highest Altman Z-Score was 5.32. The lowest was -75.22. And the median was -10.46.


Awakn Life Sciences Altman Z-Score Historical Data

The historical data trend for Awakn Life Sciences's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Awakn Life Sciences Altman Z-Score Chart

Awakn Life Sciences Annual Data
Trend Jan21 Jan22 Jan23
Altman Z-Score
- -3.24 -14.60

Awakn Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.71 -14.60 -14.09 -75.22 -61.76

Competitive Comparison of Awakn Life Sciences's Altman Z-Score

For the Biotechnology subindustry, Awakn Life Sciences's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Awakn Life Sciences's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Awakn Life Sciences's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Awakn Life Sciences's Altman Z-Score falls into.



Awakn Life Sciences Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Awakn Life Sciences's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-0.9158+1.4*-27.4309+3.3*-8.2374+0.6*3.7256+1.0*1.9259
=-62.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Oct. 2023:
Total Assets was $0.80 Mil.
Total Current Assets was $0.76 Mil.
Total Current Liabilities was $1.49 Mil.
Retained Earnings was $-21.84 Mil.
Pre-Tax Income was -0.472 + -0.871 + -1.246 + -4.081 = $-6.67 Mil.
Interest Expense was 0 + 0 + -0.05 + -0.063 = $-0.11 Mil.
Revenue was 0.021 + 0.019 + 0.379 + 1.114 = $1.53 Mil.
Market Cap (Today) was $5.54 Mil.
Total Liabilities was $1.49 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.758 - 1.487)/0.796
=-0.9158

X2=Retained Earnings/Total Assets
=-21.835/0.796
=-27.4309

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-6.67 - -0.113)/0.796
=-8.2374

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=5.540/1.487
=3.7256

X5=Revenue/Total Assets
=1.533/0.796
=1.9259

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Awakn Life Sciences has a Altman Z-Score of -62.52 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Awakn Life Sciences  (OTCPK:AWKNF) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Awakn Life Sciences Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Awakn Life Sciences's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Awakn Life Sciences (Awakn Life Sciences) Business Description

Traded in Other Exchanges
Address
301?217 Queen Street West, Toronto, ON, CAN, M5V 0R2
Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting the people in the US and key international markets and many people globally for which the current standard of care is inadequate, enabling to provide breakthrough therapeutics to addiction sufferers in desperate need.

Awakn Life Sciences (Awakn Life Sciences) Headlines